We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Proxima Demonstrated at NVIC Congress Following Significant New Business Win in Benelux

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

1607SPH - Proxima system.jpg

 The Proxima™ patient dedicated in-line blood gas monitoring system

Sphere Medical is exhibiting its Proxima™ patient dedicated arterial blood gas monitoring system and discussing its latest sale to a large teaching hospital in Benelux. Attendees of the NVIC (Dutch Intensive Care Society) Najaarscongres 2016, in Veenendaal from 22-23rd September can view and find out how the unique Proxima system supports rapid and frequent critical measurements in an intensive care unit without leaving the patient’s bedside. 

The first sale of Proxima in Benelux is to the Universitair Ziekenhuis Brussel, a 700 bed teaching hospital conducting scientific research, which has evaluated the Proxima system during the past year. After the UK and Germany, Belgium is the third country in which Sphere Medical has sold Proxima devices through its direct sales force. This includes Petra Maissan, Benelux Sales Manager for Sphere Medical, who is qualified as a Nurse Anaesthetist and therefore very well placed to offer in depth discussion on the clinical value of Proxima on Sphere’s Stand #6 at the NVIC Najaarscongres.

Dr Wolfgang Rencken, Chief Executive Officer of Sphere Medical,said, “Proxima is an innovative product which offers better patient management during a patient’s critical period, and faster and more frequent production of blood gas, electrolyte and metabolite results. We are pleased to bring Proxima to patients around Europe and report sales in three countries now. As we look ahead to the launch of Proxima 4, the opportunity to increase potential coverage from around 10% of critical care patients to 40-50% gives us optimism for the future.”